RA
PRNB

Royce & Associates’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Royce & Associates’s Portfolio PRNB Stock Details PRNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-719
Closed -$20K – 1203
2019
Q3 		$20K Buy
719
+187
+35% +$6.86K ﹤0.01% 1112
2019
Q2 		$18K Sell
532
-74
-12% -$2.31K ﹤0.01% 1121
2019
Q1 		$21K Buy
+606
New +$19.3K ﹤0.01% 1122

Other funds holding PRNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates's PRNB Position: Q4 2019 in Review

Royce & Associates sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q4 2019, closing a stake of 719 shares — an estimated $20K sold.

Royce & Associates first reported a position in PRNB in Q1 2019 and held it in 3 quarters. The position peaked at $21K in Q1 2019. 115 funds tracked by Wall St. Rank hold PRNB as of Q4 2019.

  • Royce & Associates reported no remaining Principia Biopharma Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Royce & Associates sold 719 Principia Biopharma Inc. Common Stock shares in Q4 2019, an estimated $20K.
  • Royce & Associates first reported a position in Principia Biopharma Inc. Common Stock in Q1 2019 and held it in 3 quarters.
  • Royce & Associates's Principia Biopharma Inc. Common Stock position peaked at $21K in Q1 2019.
  • 115 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q4 2019.

Based on Royce & Associates's 13F filing for Q4 2019, filed 6 Feb 2020.